Nathan Tinker Executive Director New York Biotechnology Association

1. New York BizBio 2009 Fighting for a Healthy Biotech Industry Nathan Tinker Executive Director New York Biotechnology Association

2. NYBA the voice of New York’s bioscience industry • 250 member companies • Advocacy • Public Policy • Annual Bio Advocacy Day • Relationships with State and Federal delegations • Networking • Annual Meeting (April 20-21, NYC) • NewX2 Biocruise (June 19) • Regional events • LinkedIn community • Information • State of the Industry Report • Website • Member news • Industry and competitive intelligence

3. Better Health Care, Health & Quality of Life New Medical Devices, Tests, Drugs & Related Services Research Discovery Technology Transfer & Business Development + New Jobs Why is bioscience important to New York?

4. New York bioscience is . . . state-wide

5. biotechnology life sciences research medical devices medicinal botanical manufacturing pharmaceutical preparation manufacturing in-vitro diagnostic substance manufacturing biological product manufacturing New York bioscience is . . . business 746 establishments

6. New York bioscience is . . . economic impact $16 billion in direct economic output $29 billion in total economic output

7. New York bioscience is . . . wages $3.8 billion in direct wages • Total biomedical wages in New York rose 16.9% 2003-2006 % Change Drug & Chemical Mfg 13.8% Labs & Research 17.1% Med Equip & Supplies 22.3%

8. New York bioscience is . . . tax revenue $121 million in direct State taxes

9. New York bioscience is . . . clinical trials 5,053 clinical trial sites (2nd in the nation)

10. New York bioscience is . . . jobs 55,446 direct 75,018 indirect/induced 130,464

11. New York bioscience is . . . jobs 55,446 direct

12. New York bioscience is . . . 6.8% of all biopharmaceutical output nationally

13. but . . .

14. There is no state strategy for biopharma economic development and no structure to develop one.

15. Critical requirements • Discovery, Innovation and Technology Development State funding to fill gap in shrinking federal support of scientific innovation and new technology development • Financing, Investment and Business Development Funding and business resources to support early-stage corporate development in the capital-intensive life sciences industry • Facilities, Incubation and Expansion Appropriate facilities (lab space, prototyping, & manufacturing) and infrastructure to support nascent and expanding companies • Workforce, Training and Entrepreneurship Institutional- and community-based initiatives to continue expanding skilled, multi-disciplinary workforce to support industry growth • Taxes, Incentives and Quality of Life Pro-business programs and incentives – and program application assistance- to improve economic conditions for new and expanding companies and their employees • Marketing, Outreach and Strategic Networking Statewide, asset- and opportunity-driven attraction and retention plan

16. Massachusetts’s loss, New York’s gain? • Boston Globe, Jan 22 & 28 Recent Massachusetts legislation, aimed at promoting cost containment and transparency in health care, included a provision that would forbid any kind of payments from biopharma companies or medical device manufacturing companies to a doctor in the State of Massachusetts, including clinical trials and other vital research. Result: • MA companies have begun looking elsewhere. • Major conventions have cancelled contracts.

17. How can Albany help? • Maintain a supportive regulatory environment • Protect patient access to drugs, devices and therapeutics • Expand the QETC • Provide full funding the Empire State Stem Cell Initiative

18. Facts to remember • 55,000+ direct jobs • 75,000+ indirect/induced jobs • $16 billion in direct economic impact • $121 million in state taxes • $3.8 billion in direct wages • 6.8% of all direct biopharmaceutical output nationally

19. Nathan Tinker NYBA www.nyba.org ntinker@nyba.org (631) 444-8895